Updated Results From DREAMM-3, a Phase 3 Study of Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Dexamethasone in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)

被引：0
|
作者：
Hungria, Vania T. M. [1 ]
Weisel, Katja [2 ]
Radinoff, Atanas [3 ]
Delimpasi, Sosana [4 ]
Mikala, Gabor [5 ]
Masszi, Tamas [6 ]
Li, Jian [7 ]
Capra, Marcelo [8 ]
Maiolino, Angelo [9 ]
Pappa, Vasiliki [10 ]
Chraniuk, Dominik [11 ]
Osipov, Iurii [12 ]
Leleu, Xavier [13 ]
Low, Michael [14 ]
Kouri, Fotini [15 ]
Liboon, John [16 ]
Brawley, Chris [17 ]
Lewis, Eric [18 ]
Tubel, Gabriela
Li, Mary [18 ]
McKeown, Astrid
Roy-Ghanta, Sumita [18 ]
Opalinska, Joanna [18 ]
Dimopoulos, Meletios [19 ]
机构：
[1] Clin Sao Germano Sao Paulo, Dept Hematol, Sao Paulo, Brazil
[2] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[3] Univ Hosp St Ivan Rilski EAD, Dept Clin Hematol, Sofia, Bulgaria
[4] Gen Hosp Evangelismos, Athens, Greece
[5] Natl Inst Haematol & Infect Dis, Dept Hematol & Stem Cell Transplantat, South Pest Cent Hosp, Budapest, Hungary
[6] Semmelweis Univ, Dept Internal Med & Hematol, Budapest, Hungary
[7] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China
[8] Hosp Mae Deus, Ctr Integrado Hematol Oncol, Porto Alegre, RS, Brazil
[9] Inst Amer Ensino Pesquisa & Inovacao, Rio De Janeiro, Brazil
[10] Univ Gen Hosp Attikon, Hematol Unit, Dept Internal Med & Res Unit 2, Athens, Greece
[11] Wojewodzki Szpital Zespolony, Dept Hematol, Torun, Poland
[12] VA Almazov Natl Med Res Ctr, St Petersburg, Russia
[13] CHU Poitiers, PRC, Hematol, Poitiers, France
[14] Clayton Univ, Monash Univ, Monash Hlth, Monash Haematol, Clayton, Vic, Australia
[15] GSK, Stevenage, Herts, England
[16] GSK, San Diego, CA USA
[17] GSK, London, England
[18] GSK, Upper Providence, PA USA
[19] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-395
引用
收藏
页码：S261 / S262
页数：2
相关论文
共 50 条
  • [31] Patient-Reported Experiences during and Following Treatment with Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM) in the DREAMM-2 Study
    Eliason, Laurie
    Correll, Julia
    Martin, Mona
    Cardellino, Anna
    Opalinska, Joanna
    Piontek, Trisha
    Gorsh, Boris
    Sapra, Sandhya
    Popat, Rakesh
    BLOOD, 2020, 136
  • [32] Low-dose belantamab mafodotin (belamaf) in combination with nirogacestat vs belamaf monotherapy in patients with relapsed/refractory multiple myeloma (RRMM): phase I/II DREAMM-5 platform sub-study 3
    Leypoldt, L.
    Callander, N. S.
    Richardson, P. G.
    Hus, M.
    Ribrag, V.
    Lopez, J. M.
    Kim, K.
    Lee, J. H.
    Dimopoulos, M. A.
    Schjesvold, F.
    Facon, T.
    Jo, J. -C.
    Min, C. -K.
    Mielnik, M.
    Cheng, S.
    Smith, L. M.
    Breitbach, C. J.
    Brawley, C.
    Sembhi, H.
    LaMacchia, J.
    Grosicki, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 176 - 177
  • [33] Apollo: Phase 3 Randomized Study of Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Dimopoulos, Meletios A.
    Terpos, Evangelos
    Boccadoro, Mario
    Delimpasi, Sosana
    Beksac, Meral
    Katodritou, Eirini
    Moreau, Philippe
    Baldini, Luca
    Symeonidis, Argiris
    Bila, Jelena
    Oriol, Albert
    Mateos, Maria-Victoria
    Einsele, Hermann
    Orfanidis, Ioannis
    Ahmadi, Tahamtan
    Ukropec, Jon
    Kampfenkel, Tobias
    Schecter, Jordan
    Qiu, Yanping
    Amin, Himal
    Vermeulen, Jessica
    Carson, Robin
    Sonneveld, Pieter
    BLOOD, 2020, 136
  • [34] Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Nooka, Ajay
    Lee, Hans C.
    Badros, Ashraf Z.
    Voorhees, Peter
    Hultcrantz, Malin
    Karlin, Lionel
    Arnulf, Bertrand
    Richardson, Paul G.
    Zhi, Eric
    Baron, January
    Piontek, Trisha
    Lewis, Eric
    Opalinska, Joanna
    Gupta, Ira
    Cohen, Adam D.
    Lonial, Sagar
    BLOOD, 2020, 136
  • [35] Population Pharmacokinetics (PopPK) and Exposure-Response (E-R) Analyses for Belantamab Mafodotin Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Enrolled in DREAMM-2 and DREAMM-3
    Ferron-Brady, Geraldine
    Taylor, Adekemi
    Kaullen, Josh
    Polireddy, Kishore
    McKeown, Astrid
    Sule, Neal
    Struemper, Herbert
    BLOOD, 2023, 142
  • [36] DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Rifkin, Robert
    Boyd, Kevin
    Grosicki, Sebastian
    Kim, Kihyun
    Di Raimondo, Francesco
    Dimopoulos, Meletios
    Weisel, Katja
    Arnulf, Bertrand
    Hajek, Roman
    Hungria, Vania
    Spencer, Andrew
    Davis, Randy
    Riccio, Antonio
    Kim, Chanbin
    Wilkes, Jodie
    Rutledge, Ruth
    Talekar, Mala
    Kremer, Brandon E.
    Gupta, Ira
    Mateos Manteca, Maria Victoria
    BRITISH JOURNAL OF HAEMATOLOGY, 2021, 193 : 172 - 173
  • [37] Safety and Clinical Activity of Belantamab Mafodotin With Lenalidomide Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-6 Arm-A Interim Analysis
    Quach, Hang
    Gironella, Mercedes
    Lee, Cindy
    Popat, Rakesh
    Cannell, Paul
    Kasinathan, Ravi S.
    Chopra, Bikramjit
    Rogers, Rachel
    Ferron-Brady, Geraldine
    Shafi-Harji, Seema
    Patel, Nashita
    Opalinska, Joanna
    Gupta, Ira
    Augustson, Bradley
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S423 - S424
  • [38] DREAMM-5 platform trial: Belantamab Mafodotin (GSK2857916; belamaf; BLENREP) in combination with five different novel agents in patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Weisel, K.
    Richardson, P. G.
    Trudel, S.
    Callander, N.
    Nooka, A.
    Song, K.
    Uttervall, K.
    Minnema, M. C.
    Rodriguez-Otero, P.
    Struemper, H.
    Yeakey, A.
    de Oca, Montes R.
    Smith, L. M.
    Jackson, N.
    Kaisermann, M.
    Im, E.
    Basile, F. G.
    Ahlers, C. M.
    Holkova, B.
    Gupta, I
    Kremer, B. E.
    Quach, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 204 - 205
  • [39] Safety and clinical activity of belantamab mafodotin with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-4 Study.
    Suvannasankha, Attaya
    Bahlis, Nizar J.
    Trudel, Suzanne
    Weisel, Katja
    Koenecke, Christian
    Rocafiguera, Albert Oriol
    Voorhees, Peter M.
    Alonso, Aranzazu Alonso
    Callander, Natalie Scott
    Mateos, Maria-Victoria
    Reddy, Nishitha
    Hakim, Shawn
    Patel, Nashita
    Williams, Danae
    Jewell, Roxanne C.
    Zhou, Xiangdong
    Gupta, Ira V.
    Nooka, Ajay K.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [40] DREAMM-2: Single-agent belantamab mafodotin (belamaf; GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) - outcomes by prior therapies
    Weisel, K.
    Lonial, S.
    Lee, H.
    Badros, A.
    Trudel, S.
    Nooka, A.
    Chari, A.
    Abdallah, A-O
    Callander, N.
    Sborov, D.
    Suvannasankha, A.
    Vorhees, P.
    Opalinska, J.
    Hoos, A.
    Zhi, E.
    Baron, J.
    Piontek, T.
    Jewell, R.
    Gupta, I
    Cohen, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 109 - 110
12345